Gene mutations in lung cancer: Promising predictive factors for the success of molecular therapy

PLoS Medicine

Volumn 2, Issue , 2005, Pages 0020-0022

  Inoue, Akira ^a   Nukiwa, Toshihiro ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEFITINIB; RAS PROTEIN; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE SEVERITY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG INJURY; LUNG NON SMALL CELL CANCER; ONCOGENE RAS; PROTEIN EXPRESSION; SHORT SURVEY; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; DRUG EFFECT; GENETICS; LUNG TUMOR; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PREDICTIVE VALUE; REVIEW; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 15744372126     PISSN: 15491277     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020013     Document Type: Short Survey

References (12)

1. Dy GK, Adjei AA (2002) Novel targets for lung cancer therapy: Part II. J Clin Oncol 20: 3016-3028.
2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246.
3. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290: 2149-2158.
4. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22: 777-784.
5. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22: 785-794.
6. Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, et al. (2004) A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial [abstract]. J Clin Oncol 22 (July 15 Suppl): 7022. Available: http://www.asco.org/ac/1,1003,_12-002643-00_18-0026-00_19-00678,00.asp. Accessed 24 November 2004.
7. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
9. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
10. Huncharek M, Muscat J, Geschwind JF (1999) K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: A combined analysis of 881 cases. Carcinogenesis 20: 1507-1510.
11. Pao W, Wang TY, Riely GJ, Miller VA, QiuluPan, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
12. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, et al. (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139.